SCHEDULE 13G 0001463928 XXXXXXXX LIVE Common Stock 06/16/2025 0001671584 Aptevo Therapeutics Inc. 03835L504 2401 4th Avenue, Suite 1050 Seattle WA 98121 Rule 13d-1(c) YA II PN, Ltd. a E9 0.00 357842.00 0.00 357842.00 357842.00 N 9.99 OO Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer. YA Global Investments II (U.S.), LP a DE 0.00 357842.00 0.00 357842.00 357842.00 N 9.99 OO Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer. Yorkville Advisors Global, LP a DE 0.00 357842.00 0.00 357842.00 357842.00 N 9.99 OO Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer. Yorkville Advisors Global II, LLC a DE 0.00 357842.00 0.00 357842.00 357842.00 N 9.99 OO Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer. YAII GP, LP a DE 0.00 357842.00 0.00 357842.00 357842.00 N 9.99 OO Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer. YAII GP II, LLC a DE 0.00 357842.00 0.00 357842.00 357842.00 N 9.99 OO Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer. Mark Angelo a NJ 0.00 357842.00 0.00 357842.00 357842.00 N 9.99 OO Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer. SC-Sigma Global Partners, LP a DE 0.00 357842.00 0.00 357842.00 357842.00 N 9.99 OO Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer. Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA, 98121 YA II PN, Ltd. 1012 Springfield Ave., Mountainside, NJ 07092 Cayman Islands N OO 357,842 9.99 0 357,842 0 357,842 Y Y Y N YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with Aptevo Therapeutics Inc. (the "Issuer"), on June 16, 2025. Under the SEPA, the Issuer has the option to sell up to $25 million of its Common Stock to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of shares of Common Stock then beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding shares of Common Stock of the Issuer. YA II is beneficially owned by YA Global Investments II (U.S.), LP (the "YA Feeder"). Yorkville Advisors Global, LP (the "YA Advisor") is the investment manager to YA II. Yorkville Advisors Global II, LLC (the "YA Advisor GP") is the general partner to the YA Advisor. YAII GP, LP (the "YA GP") is the general partner to the YA Feeder. YAII GP II, LLC (the "Yorkville GP") is the general partner to the YA GP. Mark Angelo makes the investment decisions on behalf of YA II. Accordingly, each of YA II, YA Feeder, the YA Advisor, the YA Advisor GP, the YA GP, the Yorkville GP and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of Class A Shares. YAII GP, LP is the general partner of SC-Sigma Global Partners, LP ("SC-Sigma"), which is an investor in YA II. YAII GP II, LLC is the general partner of YAII GP, LP. The YA Advisor is the investment manager to SC-Sigma. Accordingly, SC-Sigma, the YA GP, the Yorkville GP, the YA Advisor, and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of shares of Class A Shares. For purposes of this filing, each of the reporting persons is deemed an affiliate of each other reporting person. Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. YA II PN, Ltd. /s/ David Gonzalez 06/24/2025 YA Global Investments II (U.S.), LP /s/ David Gonzalez 06/24/2025 Yorkville Advisors Global, LP /s/ David Gonzalez 06/24/2025 Yorkville Advisors Global II, LLC /s/ David Gonzalez 06/24/2025 YAII GP, LP /s/ David Gonzalez 06/24/2025 YAII GP II, LLC /s/ David Gonzalez 06/24/2025 Mark Angelo /s/ Mark Angelo 06/24/2025 SC-Sigma Global Partners, LP /s/ David Gonzalez 06/24/2025